However, due to the new findings in this economic evaluation about osimertinib versus the comparator EGFR-TKI, reflecting the general clinical practice of managing advanced NSCLC, they might be a valuable reference for physicians and policy makers in China. Here, EGFR is linked to non-small cell lung carcinoma.